ClinicalTrials.gg
CompletedNCT01547598Updated Aug 15, 2014Results posted

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

A Phase 4 interventional study of travoprost ophthalmic solution 0.004% and travoprost 0.004% / timolol 0.5% combination ophthalmic solution in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-15.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
23rd of 45
135 · median 135
Started
2011
with 8 others
Phase 4
22 of 46
2 open now
Registered
35th of 46
by date
Lead sponsor
2 of 46
Allergan

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 23rd largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 22 in phase 4, and was the 35th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution 0.004%) monotherapy.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Open angle glaucoma or ocular hypertension
  • Best corrected visual acuity of 20/100 or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • Ocular surgery within 3 months, or anticipated ocular surgery within 12 weeks
  • Previous treatment with LUMIGAN® RC or DuoTrav®
  • History of LASIK, LASEK, RK or PRK in the study eye(s)
  • Active ocular inflammation
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
135 participants (actual)

Study arms

  • Active comparator
    LUMIGAN® RC

    Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.

    Drug: travoprost ophthalmic solution 0.004% · Drug: Bimatoprost ophthalmic solution 0.01%

  • Active comparator
    DuoTrav®

    Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.

    Drug: travoprost ophthalmic solution 0.004% · Drug: travoprost 0.004% / timolol 0.5% combination ophthalmic solution

Interventions

  • Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.

    Also known as: Travatan® Z

  • Drugtravoprost 0.004% / timolol 0.5% combination ophthalmic solution

    Drug page: Travoprost

    DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.

    Also known as: DuoTrav®

  • LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.

    Also known as: LUMIGAN® RC

06

What researchers measure

Primary outcomes

  1. Mean Diurnal Intraocular Pressure (IOP)

    IOP is a measurement of the fluid pressure inside the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each study eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Mean IOP at Week 12

    IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 12. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12

  2. Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline

    IOP is a measurement of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.

    Time frame: Baseline, Week 12

  3. Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg

    IOP is a measure of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.

    Time frame: Week 12

  4. Change From Baseline in Mean IOP at Week 6

    IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 6. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 6

07

Results

Posted Aug 15, 2014

Participant flow

Participant flow — Overall Study
MilestoneLUMIGAN® RCDuoTrav®
Started6768
Completed6163
Not completed65
Withdrew: Withdrew consent11
Withdrew: Lost to follow-up11
Withdrew: Adverse event11
Withdrew: Protocol violation11
Withdrew: Other miscellaneous reasons21

Outcome measures

PrimaryMean Diurnal Intraocular Pressure (IOP)

IOP is a measurement of the fluid pressure inside the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each study eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.

Time frame:
Week 12
Reported as:
Mean · mmHg
Mean Diurnal Intraocular Pressure (IOP)
mmHgLUMIGAN® RCDuoTrav®
Mean Diurnal Intraocular Pressure (IOP)18.6 ± 3.517.4 ± 2.7
SecondaryChange From Baseline in Mean IOP at Week 12

IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 12. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · mmHg
Change From Baseline in Mean IOP at Week 12
mmHgLUMIGAN® RCDuoTrav®
Baseline_8 AM22.0 ± 2.922.0 ± 4.1
Change from Baseline at Week 12 _8 AM (n=61,63)-2.7 ± 3.4-4.5 ± 3.1
Baseline_12 Noon20.6 ± 3.220.3 ± 3.8
Change from Baseline at Week 12_12 Noon (n=61,63)-1.9 ± 3.1-2.3 ± 3.2
Baseline_4 PM19.8 ± 3.119.8 ± 4.1
Change from Baseline at Week 12_4 PM (n=61,63)-1.3 ± 2.7-2.4 ± 3.5
SecondaryPercentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline

IOP is a measurement of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline
percentage of participantsLUMIGAN® RCDuoTrav®
Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline26.247.6
SecondaryPercentage of Participants With Mean Diurnal IOP Less Than 18 mmHg

IOP is a measure of the fluid pressure in the eye. The mean diurnal IOP was the average of the IOP values of the study eye (worse eye) at Week 12 measured at 8 AM, 12 Noon and 4 PM. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg
percentage of participantsLUMIGAN® RCDuoTrav®
Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg11.517.5
SecondaryChange From Baseline in Mean IOP at Week 6

IOP is a measurement of the fluid pressure inside the eye. IOP of the study eye (worse eye) was measured at 8 AM, 12 Noon and 4 PM at Week 6. For each eye, IOP was either the average of 2 measurements, or, if a third measurement was required, the average of 3 measurements. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 6
Reported as:
Mean · mmHg
Change From Baseline in Mean IOP at Week 6
mmHgLUMIGAN® RCDuoTrav®
Baseline_ 8 AM22.0 ± 2.922.0 ± 4.1
Change from Baseline at Week 6 _8 AM (n=66,64)-2.8 ± 2.9-4.8 ± 4.1
Baseline_12 Noon20.6 ± 3.220.3 ± 3.8
Change from Baseline at Week 6_12 Noon (n=66,64)-2.1 ± 3.1-2.8 ± 3.4
Baseline_4 PM19.8 ± 3.119.8 ± 4.1
Change from Baseline at Week 6_4 PM (n=66,64)-1.5 ± 2.5-2.9 ± 3.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travatan® Z—0/135 (0%)0/135 (0%)
LUMIGAN® RC—0/67 (0%)0/67 (0%)
DuoTrav®—1/68 (1.5%)0/68 (0%)
Most frequent serious events
Most frequent serious events
EventTravatan® ZLUMIGAN® RCDuoTrav®
PyrexiaGeneral disorders0/1350/671/68
CellulitisInfections and infestations0/1350/671/68

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LUMIGAN® RCDuoTrav®Total
Mean67.2 ± 9.765.2 ± 10.766.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)LUMIGAN® RCDuoTrav®Total
Female404080
Male272855
08

Study locations

1 site
  • Vancouver, British Columbia, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2012
First posted
Mar 8, 2012
Start
Dec 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Aug 15, 2014
Last update
Aug 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01547598
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Mar 8, 2012
Start date
Dec 2011
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Aug 15, 2014
Last update
Aug 15, 2014

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Travoprost · Bimatoprost Ophthalmic Solution

Start the discussion